湖北广济药业股份有限公司 2025年度业绩预告

Group 1 - The company expects a net profit to be negative for the fiscal year 2025, with the reporting period from January 1, 2025, to December 31, 2025 [2] - The company has communicated with its accounting firm regarding the performance forecast, and there are no significant disagreements on this matter [2][3] - The decline in performance is attributed to intensified market competition, leading to prolonged low sales prices for the company's main products, resulting in operational losses [3] Group 2 - Some of the company's subsidiaries have not shown effective improvement in their operations and continue to incur losses [3] - The company has recognized impairment signs in certain assets due to insufficient production line operation rates and declining market prices, and will make provisions for impairment based on professional evaluations [3]